/
iBio, Inc. (also referred to as "we", "us", "our", "iBio", or the "Company") is a preclinical stage biotechnology company leveraging the power of Artificial Intelligence ( AI ) for the development of hard-to-drug precision antibodies in the cardiometabolic and obesity space. Our core mission is to harness the potential of AI and machine learning ( ML ) to unveil novel biologics which other scie…
The business is unprofitable at the operating level (-4650.50% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 77.8% YoY with margins expanding 2742.4pp.
ROIC dropped from -45.49% to -67.61%, capital efficiency is deteriorating. Negative free cash flow of -$15M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (FY)
$400K
▲ +77.8% YoY
Net Income (TTM)
-$28M
▲ +26.2% YoY
Op. Margin
-4650.50%
▲ +2742.4pp YoY
ROIC
-42.25%
▼ -22.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$22M
▲ +18.4% YoY
Op. Cash Flow (TTM)
-$22M
▲ +17.5% YoY
Net Debt
-$72M
Net Cash Position
Cash & Equiv.
$75M
5Y CAGR: -24.6%
Continue Research